Baxter International Inc. 2004 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 10-K for Baxter International Inc. for the fiscal year ended December 31, 2004. Baxter is a global diversified medical products and services company operating in three segments: Medication Delivery (IV solutions, pumps, and specialty pharmaceuticals), BioScience (biopharmaceuticals, vaccines, and blood collection), and Renal (kidney dialysis products and services). The company manufactures in 28 countries and sells in over 100 countries, with approximately 50% of revenues generated outside the United States. As of December 31, 2004, the company employed approximately 48,000 people.
Key Financial Metrics
The provided text incorporates detailed financial statements by reference to the Annual Report to Stockholders; therefore, specific consolidated revenue, net income, and cash flow totals are not explicitly stated in this filing text. However, the following specific financial data points are disclosed:
- Research and Development (R&D): $517 million in 2004 (compared to $553 million in 2003).
- Capital Expenditures: $558 million in 2004 (compared to $792 million in 2003).
- Key Product Sales: Sales of ADVATE (recombinant Factor VIII) exceeded $280 million in its first full year on the market.
- Valuation and Reserves (in millions):
- Allowance for doubtful accounts: $147 million (ending balance).
- Inventory reserves: $142 million (ending balance).
- Litigation reserves: $168 million (ending balance).
- Deferred tax asset valuation allowance: $288 million (ending balance).
- Market Data: As of March 4, 2005, 619,703,972 shares of common stock were outstanding. The aggregate market value of voting common equity held by non-affiliates as of June 30, 2004, was approximately $21.2 billion.
Material Changes and Operational Highlights
Segment Performance and Developments:
- Medication Delivery: Expanded generic injectable portfolio and fulfilled U.S. government bio-defense contracts. Received FDA clearance for wireless pump connectivity (COLLEAGUE CX) and continued conversion of manufacturing lines for bar-coding compliance.
- BioScience: Launched ADVATE in 12 European countries. Filed for regulatory approval of a next-generation liquid formulation intravenous immune globulin in the U.S. and Europe.
- Renal: Expanded low-cost peritoneal dialysis (PD) therapy in emerging markets (e.g., India) and received an expanded FDA indication for EXTRANEAL in the U.S.
Financial Restatement: The company restated its consolidated financial statements for 2001, 2002, 2003, and the first three quarters of 2004. This was due to a material weakness in internal controls over the accounting for income taxes, specifically regarding the reconciliation of current income taxes payable and deferred tax assets/liabilities.
Guidance, Risks, and Contingencies
Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2004, due to the material weakness in income tax accounting. The independent auditor issued an adverse opinion on the effectiveness of internal control over financial reporting.
Legal Proceedings and Contingencies:
- Product Liability: Significant ongoing litigation includes mammary implant claims (67 lawsuits pending as of year-end), plasma-based therapies (HIV/Hepatitis C claims), and Thimerosal vaccine claims (148 lawsuits). The company maintains litigation reserves of $168 million but notes that resolution could result in losses in excess of reserves.
- Securities Litigation: Multiple class action lawsuits are pending regarding the financial restatement and alleged misleading statements. The Seventh Circuit Court of Appeals reversed a dismissal of a consolidated class action in July 2004, and the case was remanded to the District Court.
- Pricing Investigations: The company is a defendant in 19 lawsuits alleging artificially inflated average wholesale prices for Medicare/Medicaid drugs, with investigations ongoing by various state attorneys general.
Forward-Looking Risks: Key risks include currency fluctuations (a strong U.S. dollar could negatively impact reported international sales), regulatory actions (FDA delays or recalls), competitive pricing pressure (especially from generics and Group Purchasing Organizations), and the ability to realize benefits from restructuring initiatives.
Investor Verification Checklist
- Restatement Impact: Verify the specific financial adjustments made to the 2001-2004 periods due to the income tax accounting error and the current status of the remediation plan.
- Internal Control Remediation: Confirm the progress of the new reconciliation procedures and the relocation of transaction processing to Costa Rica and outsourcing in Europe to ensure the material weakness is resolved.
- Litigation Exposure: Review the latest status of the mammary implant, plasma-based therapy, and securities class action lawsuits to assess potential liabilities beyond the $168 million litigation reserve.
- ADVATE Performance: Monitor the commercial performance of ADVATE in Europe and the status of its regulatory approval in Japan and the U.S. as a key growth driver.
- Competitive Landscape: Assess the impact of generic competition on the Medication Delivery segment, particularly regarding propofol and other injectable drugs.